CovidResearchTrials by Shray Alag


CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)


HP:0030149: Cardiogenic shockHPO

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (0)


Name (Synonyms) Correlation

Correlated MeSH Terms (4)


Name (Synonyms) Correlation
D012770 Shock, Cardiogenic NIH 1.00
D012769 Shock, NIH 0.41
D000860 Hypoxia NIH 0.21
D012128 Respiratory Distress Syndrome, Adult NIH 0.08

Correlated HPO Terms (1)


Name (Synonyms) Correlation
HP:0012418 Hypoxemia HPO 0.21

There is one clinical trial.

Clinical Trials


1 European/Euro-ELSO Survey on Adult and Neonatal/ Pediatric COVID Patients in ECMO

In the last 10 years, severe acute respiratory infection (SARI) was responsible of multiple outbreaks putting a strain on the public health worldwide. Indeed, SARI had a relevant role in the development of pandemic and epidemic with terrible consequences such as the 2009 H1N1 pandemic which led to more than 200.000 respiratory deaths globally. In late December 2019, in Wuhan, Hubei, China, a new respiratory syndrome emerged with clinical signs of viral pneumonia and person-to-person transmission. Tests showed the appearance of a novel coronavirus, namely the 2019 novel coronavirus (COVID-19). Two other strains, the severe acute respiratory syndrome coronavirus (SARS-CoV) and Middle East respiratory syndrome coronavirus (MERS-CoV) have caused severe respiratory illnesses, sometimes fatal. In particular, the mortality rate associated with SARS-CoV and MERS-CoV, was of 10% and 37% respectively. Even though COVID-19 appeared from the first time in China, quickly it spread worldwide and cases have been described in other countries such as Thailand, Japan, South Korea, Germany, Italy, France, Iran, USA and many other countries. An early paper reported 41 patients with laboratory-confirmed COVID-19 infection in Wuhan. The median age of the patients was 49 years and mostly men (73%). Among those, 32% were admitted to the ICU because of the severe hypoxemia. The most associated comorbidities were diabetes (20%), hypertension (15%), and cardiovascular diseases (15%). On admission, 98% of the patients had bilateral multiple lobular and sub-segmental areas of consolidation. Importantly, acute respiratory distress syndrome (ARDS) developed in 29% of the patients, while acute cardiac injury in 12%, and secondary infection in 10%. Invasive mechanical ventilation was required in 10% of those patients, and two of these patients (5%) had refractory hypoxemia and received extracorporeal membrane oxygenation (ECMO). In a later retrospective report by Wang and collaborators, clinical characteristics of 138 patients with COVID-19 infection were described. ICU admission was required in 26.1% of the patients for acute respiratory distress syndrome (61.1%), arrhythmia (44.4%), and shock (30.6%). ECMO support was needed in 11% of the patients admitted to the ICU. During the period of follow-up, overall mortality was 4.3%. The use of ECMO in COVID-19 infection is increasing due to the high transmission rate of the infection and the respiratory-related mortality. Therefore, the investigators believe that ECMO in case of severe interstitial pneumonia caused by COVID could represent a valid solution in order to avoid lung injuries related to prolonged treatment with non-invasive and invasive mechanical ventilation. In addition, ECMO could have a role for the systemic complications such as septic and cardiogenic shock as well myocarditis scenarios. Potential clinical effects and outcomes of the ECMO support in the novel coronavirus pandemic will be recorded and analyzed in our project. The researchers hypothesize that a significant percentage of patients with COVID-19 infection will require the utilize of ECMO for refactory hypoxemia, cardiogenic shock or septic shock. This study seeks to prove this hypothesis by conducting an observational retrospective/prospective study of patients in the ICU who underwent ECMO support and describe clinical features, severity of pulmonary dysfunction and risk factors of COVID-patients who need ECMO support, the incidence of ECMO use, ECMO technical characteristics, duration of ECMO, complications and outcomes of COVID-patients requiring ECMO support.

NCT04366921 COVID SARS-CoV-2 ARDS, Human Refractory Hypoxemia Cardiogenic Shock Septic Shock Extracorporeal Membrane Oxygenation
MeSH:Respiratory Distress Syndrome, Adult Shock, Cardiogenic Shock Hypoxia
HPO:Cardiogenic shock Hypoxemia

Primary Outcomes

Description: age in years

Measure: Age

Time: at baseline

Description: male/female

Measure: Gender

Time: at baseline

Description: in kilograms

Measure: Weight

Time: at baseline

Description: in meters

Measure: Height

Time: at baseline

Description: weight and height combined to calculate BMI in kg/m^2

Measure: BMI

Time: at baseline

Description: Asthma y/n, cystic fibrosis y/n, chronic obstructive pulmonary disease y/n, pulmonary hypertension y/n, pulmonary fibrosis y/n, chronic restrictive lung disease y/n

Measure: Pre-existing pulmonary disease y/n

Time: at baseline

Description: diabetes mellitus y/n, chronic renal failure y/n, ischemic heart disease y/n, heart failure y/n, chronic liver failure y/n, neurological impairment y/n

Measure: Main co-morbidities y/n

Time: at baseline

Description: in dd-mm-yyyy or mm-dd-yyyy

Measure: Date of signs of COVID-19 infection

Time: at baseline or date of occurence

Description: in dd-mm-yyyy or mm-dd-yyyy

Measure: Date of positive swab

Time: at baseline or date of occurence

Description: in days

Measure: Pre-ECMO length of hospital stay

Time: at or during ECMO-implant

Description: in days

Measure: Pre-ECMO length of ICU stay

Time: at or during ECMO-implant

Description: in days

Measure: Pre-ECMO length of mechanical ventilation days

Time: at or during ECMO-implant

Description: y/n, what kind

Measure: Use of antibiotics

Time: up to 6 months

Description: y/n, what kind

Measure: Use of anti-viral treatment

Time: up to 6 months

Description: y/n, what kind (eg prone-position, recruitment manoeuvers, neuromuscular blockade etc)

Measure: Use of second line treatment

Time: up to 6 months

Description: respiratory or cardiac

Measure: Indications for ECMO-implant

Time: at ECMO-implant

Description: veno-venous, veno-arterial or veno-venoarterial

Measure: Type of ECMO-implant

Time: at ECMO-implant

Description: peripheral or central

Measure: Type of access

Time: at ECMO-implant

Description: in dd-mm-yyyy or mm-dd-yyyy

Measure: Date of ECMO implant

Time: at ECMO-implant

Description: l/min

Measure: ECMO blood flow rate

Time: from day of ECMO-implant for every 24 hours until date of weaning or death, up to 6 months

Description: l/min

Measure: ECMO gas flow rate

Time: from day of ECMO-implant for every 24 hours until date of weaning or death, up to 6 months

Description: y/n

Measure: ECMO configuration change

Time: up to 6 months

Description: in dd-mm-yyyy or mm-dd-yyyy

Measure: Date of ECMO configuration change

Time: up to 6 months

Description: veno-venous, veno-arterial, veno-venoarterial, other

Measure: New ECMO configuration

Time: up to 6 months

Description: right ventricular failure, left ventricular failure, refractory hypoxemia

Measure: Indications for ECMO configuration change

Time: up to 6 months

Description: settings of ventilator

Measure: Ventilator setting on ECMO

Time: from day of ECMO-implant for every 24 hours until date of weaning or death, up to 6 months

Description: heparin, bivalirudin, nothing

Measure: Anticoagulation during ECMO

Time: from day of ECMO-implant for every 24 hours until date of weaning or death, up to 6 months

Description: amount of ECMO circuit changes (1, 2, 3 etc.)

Measure: Frequency of ECMO circuit change

Time: up to 6 months

Description: Hemorrhagic, infection, other complications

Measure: ECMO complications

Time: up to 6 months

Description: y/n

Measure: ECMO Weaning

Time: from day of ECMO-implant for every 24 hours until date of weaning or death, up to 6 months

Description: y/n, date

Measure: ICU discharge

Time: from day of ICU-admission for every 24 hours until date of discharge or death, up to 6 months

Measure: Main cause of death

Time: 6 months

Description: Ward, another ICU, rehabilitation center, home

Measure: Type of discharge

Time: up to 6 months

Measure: Alive/deceased

Time: 6 months


HPO Nodes


Protein Mutations 0
SNP 0